Drug intelligence / Profile preview

normal saline + dextrose water

Development stage: Unknown
Lead developer: Hellenic Institute for the Study of Sepsis
Modality: Small Molecules
Administration: Intravenous

Overview

A placebo formulation consisting of normal saline (0.9% sodium chloride) or 5% dextrose water used as an inert control in the BEYOND (Bezlotoxumab Yielded Outcomes by Addressing Personalized Needs in Clostridioides Difficile Infection) clinical trial. Conducted by the Hellenic Institute for the Study of Sepsis, this Phase 2 trial evaluated adjunctive bezlotoxumab in patients with *Clostridioides difficile* infection at high risk for unfavorable outcomes. The placebo was administered as a single intravenous infusion to match the appearance and administration of the active drug, serving as a vehicle/control rather than a therapeutic agent.

Other names: Normal saline 0.9% or 5% dextrose water

Beyond the preview

Go deeper on normal saline + dextrose water.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on normal saline + dextrose water.

Explore the full profile